These innovative compounds represent a significant advancement in the treatment of type 2 diabetes. Retatrutide, a combined GLP-1 and GIP receptor agonist, demonstrates promising efficacy in controlling blood glucose https://aoifejndd068788.bloggactivo.com/38205441/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide